10 results on '"Chuang, Chi-Mu"'
Search Results
2. Correction: Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-κB and TGF-β2 signaling
- Author
-
Lin, Sheng-Chieh, Liao, Yi-Chu, Chen, Po-Ming, Yang, Ya-Yu, Wang, Yi-Hsiang, Tung, Shiao-Lin, Chuang, Chi-Mu, Sung, Yu-Wen, Jang, Te-Hsuan, Chuang, Shuang-En, and Wang, Lu-Hai
- Published
- 2023
- Full Text
- View/download PDF
3. Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-κB and TGF-β2 signaling
- Author
-
Lin, Sheng-Chieh, Liao, Yi-Chu, Chen, Po-Ming, Yang, Ya-Yu, Wang, Yi-Hsiang, Tung, Shiao-Lin, Chuang, Chi-Mu, Sung, Yu-Wen, Jang, Te-Hsuan, Chuang, Shuang-En, and Wang, Lu-Hai
- Published
- 2022
- Full Text
- View/download PDF
4. Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review
- Author
-
Chao, Wei-Ting, Liu, Chia-Hao, Lai, Chiung-Ru, Chen, Yi-Jen, Chuang, Chi-Mu, and Wang, Peng-Hui
- Published
- 2018
- Full Text
- View/download PDF
5. Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
- Author
-
Yen-Hou Chang, Wai-Hou Li, Yi Chang, Chia-Wen Peng, Ching-Hsuan Cheng, Wei-Pin Chang, Chi-Mu Chuang, Chang, Yen-Hou, Li, Wai-Hou, Chang, Yi, Peng, Chia-Wen, Cheng, Ching-Hsuan, Chang, Wei-Pin, and Chuang, Chi-Mu
- Subjects
INTRAPERITONEAL injections ,CANCER chemotherapy ,PERITONEAL dialysis ,CANCER patients ,MORTALITY ,PATIENTS ,CARCINOGENESIS ,CISPLATIN ,COMPARATIVE studies ,INJECTIONS ,INTRAVENOUS therapy ,RESEARCH methodology ,MEDICAL cooperation ,OVARIAN tumors ,PROGNOSIS ,RESEARCH ,RISK assessment ,TUMOR classification ,PERITONEUM tumors ,EVALUATION research - Abstract
Background: In the analysis of survival data for cancer patients, the problem of competing risks is often ignored. Competing risks have been recognized as a special case of time-to-event analysis. The conventional techniques for time-to-event analysis applied in the presence of competing risks often give biased or uninterpretable results.Methods: Using a prospectively collected administrative health care database in a single institution, we identified patients diagnosed with stage III or IV primary epithelial ovarian, tubal, and peritoneal cancers with minimal residual disease after primary cytoreductive surgery between 1995 and 2012. Here, we sought to evaluate whether intraperitoneal chemotherapy outperforms intravenous chemotherapy in the presence of competing risks. Unadjusted and multivariable subdistribution hazards models were applied to this database with two types of competing risks (cancer-specific mortality and other-cause mortality) coded to measure the relative effects of intraperitoneal chemotherapy.Results: A total of 1263 patients were recruited as the initial cohort. After propensity score matching, 381 patients in each arm entered into final competing risk analysis. Cumulative incidence estimates for cancer-specific mortality were statistically significantly lower (p = 0.017, Gray test) in patients receiving intraperitoneal chemotherapy (5-year estimates, 34.5%; 95% confidence interval [CI], 29.5-39.6%, and 10-year estimates, 60.7%; 95% CI, 52.2-68.0%) versus intravenous chemotherapy (5-year estimates, 41.3%; 95% CI, 36.2-46.3%, and 10-year estimates, 67.5%, 95% CI, 61.6-72.7%). In subdistribution hazards analysis, for cancer-specific mortality, intraperitoneal chemotherapy outperforms intravenous chemotherapy (Subdistribution hazard ratio, 0.82; 95% CI, 0.70-0.96) after correcting other covariates.Conclusions: In conclusion, results from this comparative effectiveness study provide supportive evidence for previous published randomized trials that intraperitoneal chemotherapy outperforms intravenous chemotherapy even eliminating the confounding of competing risks. We suggest that implementation of competing risk analysis should be highly considered for the investigation of cancer patients who have medium to long-term follow-up period. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
6. Neurofibroma involving obturator nerve mimicking an adnexal mass: a rare case report and PRISMA-driven systematic review.
- Author
-
Chao, Wei-Ting, Liu, Chia-Hao, Chen, Yi-Jen, Wu, Hua-Hsi, Chuang, Chi-Mu, and Wang, Peng-Hui
- Subjects
NEUROFIBROMA ,ADNEXAL diseases ,SURGICAL excision ,LIPOSARCOMA ,OVARIAN cancer ,DIAGNOSIS ,THERAPEUTICS - Abstract
Background: Pelvic masses are a common gynecologic problem, and majority of them are diagnosed as ovarian tumors finally. Sometimes, it is hard to distinguish the origin of these pelvic masses. The following case is a solitary neurofibroma arising from the right-side obturator nerve, which was impressed as a right-side ovarian tumor initially. We reported this case, and also performed a PRISMA-driven systematic review to summary the similar cases in the literature. This review includes image, molecular and pathological findings and outcome of neurofibroma. Case presentation: A 33-year-old woman with a regular menstrual period denied any symptoms or signs. During her physical check-up, image examination revealed a right-side heterogeneous pelvic mass; it was suggestive of a complex of right-side ovarian tumor. A provisional diagnosis of retroperitoneal pelvic mass, probably a benign ovarian tumor, was made. Excision of the right-side pelvic mass was performed. We sent the specimens for frozen pathology, which indicated neurofibroma and lipomatous tumor and that the possibility of liposarcoma cannot be excluded. A segment of the obturator nerve was attached to the tumor and was severed. A right-side obturator nerve tear during tumor excision was observed, and a neurosurgeon was consulted for obturator nerve grafting and repair. The patient complained of mild weakness and paresthesia affecting the right leg, and we consulted a rehabilitation doctor for neuron injury. The patient’s recovery was uneventful, and she was discharged eight days after the drain was removed. Further rehabilitation treatment was arranged. Conclusion: A neurofibroma is an uncommon pelvic retroperitoneal tumor, and it can be misdiagnosed as an adnexal mass. To our knowledge, this is a rare case of a solitary neurofibroma arising from the obturator nerve. It usually does not have any neurological deficit. We present this case to demonstrate that pelvic neurofibroma can be mistaken for an adnexal mass. This fact should be borne in mind during the diagnosis process. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
- Author
-
Chang YH, Lu CH, Yen MS, Lee WH, Chang Y, Chang WP, and Chuang CM
- Subjects
- Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Ovarian Epithelial, Cisplatin therapeutic use, Cytoreduction Surgical Procedures, Drug Administration Schedule, Fallopian Tube Neoplasms surgery, Female, Humans, Injections, Intraperitoneal, Neoplasms, Glandular and Epithelial surgery, Ovarian Neoplasms surgery, Paclitaxel therapeutic use, Peritoneal Neoplasms surgery, Propensity Score, Prospective Studies, Treatment Outcome, Cisplatin administration & dosage, Fallopian Tube Neoplasms drug therapy, Neoplasms, Glandular and Epithelial drug therapy, Ovarian Neoplasms drug therapy, Paclitaxel administration & dosage, Peritoneal Neoplasms drug therapy
- Abstract
We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.
- Published
- 2016
- Full Text
- View/download PDF
8. Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
- Author
-
Chang YH, Li WH, Chang Y, Peng CW, Cheng CH, Chang WP, and Chuang CM
- Subjects
- Administration, Intravenous, Aged, Disease-Free Survival, Female, Humans, Injections, Intraperitoneal, Middle Aged, Neoplasm Staging, Neoplasm, Residual epidemiology, Neoplasm, Residual pathology, Ovarian Neoplasms epidemiology, Ovarian Neoplasms pathology, Peritoneal Neoplasms epidemiology, Peritoneal Neoplasms pathology, Risk Assessment, Cisplatin administration & dosage, Neoplasm, Residual drug therapy, Ovarian Neoplasms drug therapy, Peritoneal Neoplasms drug therapy
- Abstract
Background: In the analysis of survival data for cancer patients, the problem of competing risks is often ignored. Competing risks have been recognized as a special case of time-to-event analysis. The conventional techniques for time-to-event analysis applied in the presence of competing risks often give biased or uninterpretable results., Methods: Using a prospectively collected administrative health care database in a single institution, we identified patients diagnosed with stage III or IV primary epithelial ovarian, tubal, and peritoneal cancers with minimal residual disease after primary cytoreductive surgery between 1995 and 2012. Here, we sought to evaluate whether intraperitoneal chemotherapy outperforms intravenous chemotherapy in the presence of competing risks. Unadjusted and multivariable subdistribution hazards models were applied to this database with two types of competing risks (cancer-specific mortality and other-cause mortality) coded to measure the relative effects of intraperitoneal chemotherapy., Results: A total of 1263 patients were recruited as the initial cohort. After propensity score matching, 381 patients in each arm entered into final competing risk analysis. Cumulative incidence estimates for cancer-specific mortality were statistically significantly lower (p = 0.017, Gray test) in patients receiving intraperitoneal chemotherapy (5-year estimates, 34.5%; 95% confidence interval [CI], 29.5-39.6%, and 10-year estimates, 60.7%; 95% CI, 52.2-68.0%) versus intravenous chemotherapy (5-year estimates, 41.3%; 95% CI, 36.2-46.3%, and 10-year estimates, 67.5%, 95% CI, 61.6-72.7%). In subdistribution hazards analysis, for cancer-specific mortality, intraperitoneal chemotherapy outperforms intravenous chemotherapy (Subdistribution hazard ratio, 0.82; 95% CI, 0.70-0.96) after correcting other covariates., Conclusions: In conclusion, results from this comparative effectiveness study provide supportive evidence for previous published randomized trials that intraperitoneal chemotherapy outperforms intravenous chemotherapy even eliminating the confounding of competing risks. We suggest that implementation of competing risk analysis should be highly considered for the investigation of cancer patients who have medium to long-term follow-up period.
- Published
- 2016
- Full Text
- View/download PDF
9. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.
- Author
-
Chuang CM, Monie A, Hung CF, and Wu TC
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, Calreticulin genetics, Calreticulin immunology, Cell Line, Tumor, Female, Human papillomavirus 16 genetics, Human papillomavirus 16 immunology, Humans, Imiquimod, Killer Cells, Natural immunology, Macrophages immunology, Membrane Glycoproteins agonists, Mice, Mice, Inbred C57BL, Neoplasms, Experimental immunology, Papillomavirus E7 Proteins genetics, Papillomavirus E7 Proteins immunology, Papillomavirus Vaccines genetics, T-Lymphocytes, Regulatory immunology, Toll-Like Receptor 7 agonists, Vaccines, DNA administration & dosage, Vaccines, DNA genetics, Adjuvants, Immunologic administration & dosage, Aminoquinolines administration & dosage, Neoplasms, Experimental therapy, Papillomavirus Vaccines administration & dosage
- Abstract
Background: There is an urgent need to develop new innovative therapies for the control of advanced cancer. The combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as a potentially plausible approach for the control of advanced cancer., Methods: In the current study, we explored the combination of the DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus type 16 (HPV-16) E7 antigen (CRT/E7) with the TLR7 agonist imiquimod for their ability to generate E7-specific immune responses and antitumor effects in tumor-bearing mice., Results: We observed that treatment with CRT/E7 DNA in combination with imiquimod leads to an enhancement in the E7-specific CD8+ T cell immune responses and a decrease in the number of myeloid-derived suppressor cells in the tumor microenvironment of tumor-bearing mice. Furthermore, treatment with CRT/E7 DNA in combination with imiquimod leads to significantly improved antitumor effects and prolonged survival in treated mice. In addition, treatment with imiquimod led to increased number of NK1.1+ cells and F4/80+ cells in the tumor microenvironment. Macrophages and NK1.1+ cells were found to play an important role in the antitumor effects mediated by treatment with CRT/E7 DNA in combination with imiquimod., Conclusions: Thus, our data suggests that the combination of therapeutic HPV DNA vaccination with topical treatment with the TLR7 agonist imiquimod enhances the antitumor immunity induced by DNA vaccination. The current study has significant implications for future clinical translation.
- Published
- 2010
- Full Text
- View/download PDF
10. Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects.
- Author
-
Chuang CM, Monie A, Wu A, and Hung CF
- Subjects
- Animals, Antigens, Neoplasm metabolism, Apoptosis, Combined Modality Therapy methods, Female, HSP70 Heat-Shock Proteins metabolism, Humans, Mice, Mice, Inbred C57BL, Oncogene Proteins, Viral genetics, Papillomavirus E7 Proteins, Papillomavirus Vaccines metabolism, Vaccines, DNA therapeutic use, Antineoplastic Agents administration & dosage, Apigenin therapeutic use, Immunotherapy methods
- Abstract
Background: It is important to develop innovative therapies for advanced stage cancers in addition to the conventional therapies including chemotherapy, radiation and surgery. Antigen-specific immunotherapy has emerged as a novel alternate therapy for advanced stage cancers, which may be employed in conjunction with conventional therapies., Methods: In the current study, we tested the effect of treatment with the chemotherapeutic agent, apigenin in combination with DNA vaccines encoding the HPV-16 E7 antigen linked to heat shock protein 70 (HSP70) in the control of the E7-expressing tumor, TC-1., Results: We observed that treatment with apigenin rendered the TC-1 tumor cells more susceptible to lysis by E7-specific cytotoxic CD8+ T cells. Furthermore, treatment of TC-1 tumor cells with apigenin was found to enhance apoptotic tumor cell death in vitro in a dose-dependant manner. We showed that TC-1 tumor-bearing mice treated with apigenin combined with E7-HSP70 DNA generate highest frequency of primary and memory E7-specific CD8+ T cells, leading to potent therapeutic anti-tumor effects against E7-expressing tumors., Conclusion: Thus, apigenin represents a promising chemotherapeutic agent, which may be used in combination with immunotherapy for the treatment of advanced stage cancers. The clinical implications of the current strategy are discussed.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.